Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Capital Strength UCITS ETF 13.03.2026 FTCS. IE00BL0L0D23 275,002.00 USD 9,001,586.55 32.733 ...
-
HyperLight Demonstrates Low-Power 1.6T-DR8 TFLN-based Reference Transceiver Assembled by TFC
CAMBRIDGE, Mass.--(BUSINESS WIRE)--HyperLight Corporation (“HyperLight”) today announced a major milestone in low-power optical networking with the demonstration of a 1.6T-DR8 optical transceiver leveraging HyperLight’s TFLN Chiplet™ Platform. The reference module was demonstrated with engineering and manufacturing support from Suzhou TFC Optical Communication Co., Ltd. (SZSE: 300394, or "TFC"). The reference design achieves 20W power consumption in a fully retimed 1.6T-DR8 module, representing...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Low Duration Global Government Bond UCITS ETF 13.03.2026 FGOV LN IE00BKS2X200 58,638.00 GBP 868,081.65 17.125 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Value Line Dividend Index UCITS ETF 13.03.2026 FVD. IE00BKVKW020 250,002.00 USD 7,254,826.43 29.019 ...
-
Semtech Launches 224Gbps IC Family for Linear Optics Era
CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductor, Internet of Things (IoT) systems and cloud connectivity service solutions, today announced a family of 224Gbps per lane Transimpedance Amplifiers (TIAs) and Mach-Zehnder Modulator (MZM) drivers for half retimed (LRO), LPO, XPO, Near-Packaged Optics (NPO) and Co-Packaged Optics (CPO) interconnect applications. The new CEI-224G-Linear and LPO-MSA compliant devices enable 8...
-
Okta Announces New Blueprint for the Secure Agentic Enterprise
SAN FRANCISCO--(BUSINESS WIRE)--Okta, Inc. (NASDAQ: OKTA), the leading independent identity partner, today announced a new blueprint for the secure agentic enterprise to help every organization answer three critical questions for the agentic era: where are my agents, what can they connect to, and what can they do? To help customers implement this framework, Okta is delivering Okta for AI Agents, a comprehensive platform to discover and register known and unknown AI agents, standardize agent acc...
-
Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer
WALTHAM, Mass.--(BUSINESS WIRE)--Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. Vignola brings extensive leadership experience in corporate finance across the biotech industry. “We are excited to welcome Mark as our Chief Financial Officer, with his extensive experience as a stra...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 13.03.2026 FCSG IE00BKPSPT20 1,100,002.00 USD 46,635,487.42 42.396 ...
-
GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications
ZUG, Switzerland--(BUSINESS WIRE)--GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications...
-
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the year ended December 31, 2025. Corporate Highlights FY 2025 to Date COYA 302 Successfully launched the ALSTARS Phase 2 trial evaluating COYA 302 for the treatment of ALS and now actively...